Equillium (NASDAQ:EQ) is a biotechnology firm focused on developing therapies for severe autoimmune and inflammatory disorders. Their approach hinges on leveraging deep understanding of immunology to create innovative treatments. The company's pipeline includes projects targeting conditions such as graft-versus-host disease, uncontrolled asthma, and lupus nephritis, highlighting a commitment to addressing significant unmet medical needs. With a mission geared towards transforming the lives of patients by advancing first-in-class therapies, Equillium's strategies revolve around rigorous research, clinical development, and strategic collaborations to expedite the delivery of their therapeutic solutions to the market.